See more : Wellpool Co., Ltd. (8424.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of SI-BONE, Inc. (SIBN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SI-BONE, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Intralot S.A. Integrated Lottery Systems and Services (IRLTY) Income Statement Analysis – Financial Results
- Nomura Research Institute, Ltd. (NRILY) Income Statement Analysis – Financial Results
- Shilchar Technologies Limited (SHILCTECH.BO) Income Statement Analysis – Financial Results
- Cube Co., Ltd. (7112.T) Income Statement Analysis – Financial Results
- Voestalpine AG (VAS.DE) Income Statement Analysis – Financial Results
SI-BONE, Inc. (SIBN)
About SI-BONE, Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 138.89M | 106.41M | 90.15M | 73.39M | 67.30M | 55.38M | 47.98M | 42.10M | 41.17M | 40.05M | 49.00M | 37.02M |
| Cost of Revenue | 29.47M | 15.71M | 10.43M | 8.90M | 6.79M | 4.83M | 5.11M | 5.17M | 5.40M | 6.50M | 4.33M | 3.04M |
| Gross Profit | 109.42M | 90.70M | 79.72M | 64.49M | 60.51M | 50.55M | 42.87M | 36.94M | 35.78M | 33.55M | 44.67M | 33.98M |
| Gross Profit Ratio | 78.78% | 85.24% | 88.43% | 87.87% | 89.91% | 91.27% | 89.35% | 87.73% | 86.89% | 83.77% | 91.16% | 91.78% |
| Research & Development | 15.03M | 13.63M | 12.44M | 9.46M | 7.28M | 5.38M | 5.51M | 6.38M | 8.61M | 9.17M | 8.37M | 3.77M |
| General & Administrative | 31.07M | 28.96M | 25.07M | 19.80M | 20.98M | 12.64M | 13.06M | 12.91M | 13.79M | 10.06M | 6.85M | 5.23M |
| Selling & Marketing | 110.25M | 107.73M | 93.88M | 73.79M | 68.25M | 44.50M | 41.65M | 35.22M | 39.80M | 40.63M | 34.74M | 35.69M |
| SG&A | 141.32M | 136.69M | 118.95M | 93.59M | 89.24M | 57.14M | 54.71M | 48.12M | 53.59M | 50.68M | 41.59M | 40.92M |
| Other Expenses | 0.00 | -132.00K | 277.00K | -126.00K | -2.00K | -1.15M | 340.00K | 213.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 156.35M | 150.31M | 131.39M | 103.05M | 96.51M | 62.51M | 60.22M | 54.50M | 62.20M | 59.84M | 49.90M | 44.65M |
| Cost & Expenses | 185.82M | 166.02M | 141.82M | 111.95M | 103.30M | 67.35M | 65.33M | 59.67M | 67.60M | 66.34M | 54.23M | 47.69M |
| Interest Income | 6.92M | 1.30M | 186.00K | 1.10M | 2.55M | 769.00K | 175.00K | 71.00K | 1.66M | 1.52M | 909.00K | 226.00K |
| Interest Expense | 3.46M | 2.82M | 5.37M | 6.10M | 4.95M | 5.49M | 6.20M | 3.31M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.43M | 3.45M | 2.09M | 1.13M | 774.00K | 722.00K | 1.01M | 1.04M | 786.00K | 287.00K | 50.00K | 42.00K |
| EBITDA | -34.45M | -54.99M | -49.58M | -36.47M | -32.68M | -11.62M | -15.82M | -16.24M | -25.68M | -26.01M | -5.25M | -10.68M |
| EBITDA Ratio | -24.80% | -54.92% | -56.80% | -51.23% | -49.71% | -21.61% | -32.97% | -38.58% | -62.27% | -64.95% | -10.71% | -28.84% |
| Operating Income | -46.93M | -59.61M | -51.67M | -38.57M | -36.00M | -11.97M | -17.35M | -17.57M | -26.42M | -26.30M | -5.30M | -10.72M |
| Operating Income Ratio | -33.79% | -56.02% | -57.31% | -52.55% | -53.50% | -21.61% | -36.16% | -41.72% | -64.18% | -65.66% | -10.81% | -28.96% |
| Total Other Income/Expenses | 3.60M | -1.65M | -4.90M | -5.13M | -2.40M | -5.49M | -5.69M | -3.02M | -1.73M | -1.50M | -847.00K | -184.00K |
| Income Before Tax | -43.34M | -61.26M | -56.57M | -43.70M | -38.40M | -17.45M | -23.04M | -20.59M | -28.15M | -27.80M | -6.14M | -10.90M |
| Income Before Tax Ratio | -31.20% | -57.57% | -62.75% | -59.54% | -57.06% | -31.51% | -48.01% | -48.90% | -68.38% | -69.42% | -12.54% | -29.45% |
| Income Tax Expense | 0.00 | 1.65M | 3.56M | 4.85M | 4.17M | 5.49M | 5.69M | 3.02M | 0.00 | 2.00K | 10.00K | 0.00 |
| Net Income | -43.34M | -62.90M | -60.13M | -48.54M | -42.58M | -17.45M | -23.04M | -20.59M | -28.15M | -27.81M | -6.15M | -10.90M |
| Net Income Ratio | -31.20% | -59.11% | -66.70% | -66.15% | -63.26% | -31.51% | -48.01% | -48.90% | -68.38% | -69.42% | -12.56% | -29.45% |
| EPS | -1.13 | -1.84 | -1.81 | -1.67 | -1.72 | -1.10 | -1.66 | -1.33 | -1.17 | -10.42 | -2.69 | -5.76 |
| EPS Diluted | -1.13 | -1.84 | -1.81 | -1.67 | -1.72 | -1.10 | -1.66 | -1.33 | -1.17 | -10.42 | -2.69 | -5.76 |
| Weighted Avg Shares Out | 38.43M | 34.20M | 33.15M | 29.06M | 24.71M | 15.90M | 13.87M | 15.48M | 24.08M | 2.67M | 2.29M | 1.89M |
| Weighted Avg Shares Out (Dil) | 38.43M | 34.20M | 33.15M | 29.06M | 24.71M | 15.90M | 13.87M | 15.48M | 24.08M | 2.67M | 2.29M | 1.89M |
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York....
SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants...
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago.
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance
SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024.
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™
The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic...
Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength?
Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024
SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday,...
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device
SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation
SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant...
Source: https://incomestatements.info
Category: Stock Reports